Dermorphin 5mg is a specialized heptapeptide designed for in vitro and preclinical investigation of mu-opioid receptor mechanics. PX1 Research provides analytical-grade dermorphin manufactured in GMP-compliant USA facilities, accompanied by lot-specific certificates of analysis and comprehensive purity verification.
Dermorphin 5mg is a specialized heptapeptide designed for in vitro and preclinical investigation of mu-opioid receptor mechanics. PX1 Research provides analytical-grade dermorphin manufactured in GMP-compliant USA facilities, accompanied by lot-specific certificates of analysis and comprehensive purity verification.
Dermorphin 5mg is a high-purity, synthetic heptapeptide (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) supplied for in vitro and laboratory research. Recognized for its potent, selective affinity for the mu-opioid receptor (MOR) in preclinical models, this 5-milligram lyophilized compound incorporates a rare D-amino acid residue, imparting exceptional resistance to enzymatic degradation during receptor binding and signaling assays.
Originally discovered in the skin of South American frogs belonging to the genus *Phyllomedusa*, dermorphin represents a unique class of naturally derived opioid peptides that utilize D-amino acid substitution for bio-stabilization. In contemporary laboratory environments, research institutions utilize synthetic Dermorphin 5mg research vials to investigate receptor kinetics, G-protein coupled receptor (GPCR) activation, analgesia pathways, and peptide stability parameters without the metabolic lability typical of L-amino acid endogenous opioids.
The primary structure of dermorphin consists of seven amino acids: L-Tyrosine, D-Alanine, L-Phenylalanine, Glycine, L-Tyrosine, L-Proline, and L-Serine, terminated with a C-terminal carboxamide group. The inclusion of D-Alanine at position 2 is the defining structural feature of the molecule. Most endogenous mammalian peptides consist entirely of L-enantiomer amino acids, making them highly susceptible to rapid cleavage by serum peptidases and endopeptidases.
In contrast, the D-Ala modification in dermorphin alters the steric backbone of the peptide chain. Preclinical cleavage assays demonstrate that this modification renders the N-terminal region resistant to aminopeptidase cleavage, significantly extending its half-life in aqueous buffer systems and tissue homogenates. Researchers evaluating peptide degradation mechanics frequently benchmark novel peptidomimetics against dermorphin due to its established structural stability profile across a range of pH conditions and enzymatic environments.
In vitro radioligand binding assays indicate that dermorphin possesses an extraordinarily high affinity for the mu-opioid receptor ($μ$-OR), with dissociation constants ($K_i$) typically reported in the sub-nanomolar range. Comparative binding experiments in rodent neural membrane preparations show that dermorphin exhibits significantly higher selectivity for the mu-opioid receptor over the delta-opioid ($δ$-OR) and kappa-opioid ($κ$-OR) sub-types.
When bound to the mu-opioid receptor, dermorphin functions as a full agonist, triggering receptor conformational changes that promote GTP-gamma-S binding and subsequent inhibition of adenylyl cyclase activity. In cellular models expressing recombinant human MOR, dermorphin activation induces downstream intracellular signaling cascades, including beta-arrestin recruitment and receptor phosphorylation. These properties make mu-opioid receptor agonists like dermorphin critical reference standards in pharmacological assays designed to map GPCR activation dynamics.
To understand the relative potency and structural nuances of dermorphin, researchers often compare it against other standardized opioid receptor ligands in competitive binding and functional assays. The table and comparative data below highlight key operational differences observed in preclinical literature among representative compounds in our expanded catalog of research peptides.
While deltorphin research compounds target the delta-opioid receptor with high specificity due to variations in their C-terminal domains, dermorphin remains strictly mu-selective. Similarly, comparison with endogenous mammalian mu-agonists like endomorphin-1 highlights the dramatic stability advantage conferred by dermorphin's D-alanine residue. Whereas endomorphin-1 undergoes rapid enzymatic inactivation within minutes in rat plasma, dermorphin demonstrates prolonged structural integrity, allowing for extended incubation windows in organ bath and cell culture protocols.
Proper reconstitution of lyophilized Dermorphin 5mg is critical to preserving compound integrity and achieving accurate molar concentrations for assay execution. The peptide is supplied as a sterile, vacuum-sealed lyophilized cake. Laboratories should handle the vial using aseptic technique inside a certified laminar flow hood.
For standard aqueous stock solutions, reconstitute the 5mg mass using sterile, deionized laboratory-grade water or phosphate-buffered saline (PBS, pH 7.4). If initial dissolution is slow due to ionic concentration, a minor addition of 0.1% acetic acid can assist in solubilizing the hydrophobic aromatic residues (Tyr and Phe). Avoid aggressive vortexing or sonic agitation, as high shear forces can induce peptide aggregation or structural denaturation. Gentle inversion or mild swirling is recommended until complete optical clarity is achieved.
Lyophilized Dermorphin 5mg exhibits excellent long-term stability when stored at -20°C or -80°C in a desiccated environment away from direct light exposure. Under these conditions, the un-reconstituted powder maintains specified purity levels for up to 24 months. Upon arrival at the research facility, vials should be logged into inventory and immediately transferred to sub-zero storage.
Once reconstituted into aqueous solution, the peptide's shelf life is reduced. Stock solutions should be divided into single-use micro-aliquots using polypropylene microcentrifuge tubes to prevent repeated freeze-thaw cycles. Freeze-thaw cycling introduces localized ice-crystal formation and concentration gradients that accelerate hydrolysis and physical aggregation. Reconstituted aliquots stored at -80°C remain stable for several months, while working solutions maintained at 4°C should be utilized within 7 to 14 days.
To ensure precise baseline data in analytical testing, laboratory researchers must verify the chemical identity and chromatographic purity of their research compounds. Every lot of Dermorphin 5mg supplied by PX1 Research undergoes rigorous testing in an ISO 17025 accredited laboratory using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS).
RP-HPLC testing establishes purity by separating the target peptide from trace synthesis truncated sequences or side-reaction impurities. PX1 Research mandates a minimum purity threshold of >98% area-under-the-curve integration at 214nm and 280nm absorption wavelengths. Complementary ESI-MS analysis confirms the exact molecular weight (monoisotopic mass of 802.9 g/mol), matching theoretical mass spectra to eliminate cross-contamination risks. Detailed spectrum graphs are published on every batch certificate of analysis available through our peptide research library.
Bacterial endotoxins (lipopolysaccharides) represent a significant confounding variable in cell culture experiments, receptor binding assays, and tissue preparations. High endotoxin levels can trigger unintended inflammatory pathway activation, alter cell viability, and skew signal transduction readings in vitro.
PX1 Research enforces strict endotoxin screening protocols for all product batches using the Limulus Amebocyte Lysate (LAL) kinetic chromogenic assay in accordance with USP <85> guidelines. Our Dermorphin 5mg lots are certified to contain endotoxin levels below 0.01 EU/µg of peptide. This rigorous purification standard ensures that researchers obtain reproducible, unconfounded empirical data during delicate bioassays.
PX1 Research is dedicated to supporting academic, pharmaceutical, and institutional facilities with uncompromising quality standards. All peptide synthesis is conducted in state-of-the-art, GMP-compliant facilities located within the United States. By maintaining strict oversight of production environments, raw material sourcing, and analytical verification, we provide stable, reliable reagents for demanding scientific applications.
We maintain fully stock-managed distribution hubs in California and Arizona, allowing us to offer same-day shipping for orders placed Monday through Friday prior to cutoff times. Products are packaged in protective temperature-controlled shipping materials to preserve peptide integrity during transit. Institutional procurement departments seeking high-volume supplies or contract pricing can establish streamlined supply channels through our bulk institutional accounts portal.
What is Dermorphin 5mg used for in laboratory research?
Dermorphin 5mg is utilized strictly in laboratory settings to investigate mu-opioid receptor (MOR) kinetics, G-protein coupled receptor signaling, enzymatic resistance mechanisms, and receptor ligand interactions in preclinical models.
What is the primary sequence of dermorphin?
The primary amino acid sequence of dermorphin is H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, featuring a D-alanine residue at position 2 and a C-terminal amide group.
Why does dermorphin contain a D-amino acid?
The inclusion of D-Alanine at position 2 confers structural resistance against proteolytic degradation by serum peptidases, allowing the peptide to maintain structural stability longer than standard L-amino acid peptides.
How should Dermorphin 5mg be reconstituted for assay use?
Reconstitute the 5mg lyophilized powder using sterile deionized water or PBS (pH 7.4). Gentle swirling or mild acetic acid (0.1%) addition can facilitate solubilization without aggressive vortexing.
What storage conditions are recommended for lyophilized dermorphin?
Lyophilized Dermorphin 5mg should be stored at -20°C or -80°C in a desiccated, light-protected environment. Under these parameters, the un-reconstituted compound is stable for up to 24 months.
How does PX1 Research verify the purity of Dermorphin 5mg?
PX1 Research verifies purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm >98% purity, alongside Electrospray Ionization Mass Spectrometry (ESI-MS) for sequence mass verification.
What is the endotoxin threshold for PX1 Dermorphin 5mg?
All lots of PX1 Dermorphin 5mg undergo LAL testing to ensure endotoxin levels remain strictly below 0.01 EU/µg, preventing non-specific cellular inflammatory responses during in vitro testing.
How selective is dermorphin for the mu-opioid receptor versus delta receptors?
In vitro radioligand assays demonstrate that dermorphin exhibits high selectivity for the mu-opioid receptor, showing significantly lower binding affinity for delta- and kappa-opioid receptors.
Is Dermorphin 5mg approved for human therapeutic use or dosing?
No. Dermorphin 5mg is a synthetic research compound intended exclusively for in vitro and laboratory research. It is not for human or animal therapeutic, clinical, or diagnostic use.
What are the shipping and fulfillment timelines for PX1 Research orders?
Orders placed Monday through Friday before our afternoon cutoff time ship same-day from our fulfillment facilities located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.